- Yuhan Corp‘s operating profit for the fiscal year was 47.68 billion won.
- This figure fell short of analysts’ estimates, which were set at 94.09 billion won.
- Sales for the year reached 2.07 trillion won.
- The sales figures were slightly below expectations, which had been pegged at 2.09 trillion won.
- Investment recommendations for Yuhan Corp include 14 buy ratings, 2 hold ratings, and 2 sell ratings.
A look at Yuhan Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Yuhan Corp, a company known for manufacturing pharmaceutical products, has received positive ratings across various key factors according to Smartkarma Smart Scores. With a strong outlook in Growth, Resilience, and Momentum scoring 4 out of 5 in each category, the company seems to be positioned well for long-term success. This indicates a promising future in terms of expanding its business operations and maintaining stability in changing market conditions.
Although the Value and Dividend scores for Yuhan Corp are rated lower at 2 out of 5, the overall picture is optimistic due to the higher scores in Growth, Resilience, and Momentum. As they manufacture and market a diverse range of products including pharmaceuticals, personal care items, dietary supplements, and veterinary medicines, Yuhan Corp has a strong footing in multiple sectors which could contribute to its future growth and success.
### Yuhan Corporation manufactures and markets various pharmaceutical products on its own and through joint ventures with other global pharmaceutical companies. The Company also produces personal care products, dietary supplements, and veterinary medicines. ###
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
